AstraZeneca Full Royalty Sample Clauses

AstraZeneca Full Royalty. On a Licensed Program-by-Licensed Program basis, as partial consideration for the rights granted to AstraZeneca hereunder, subject to the provisions of this Section 6.7.1 and Section 6.7.2, AstraZeneca will pay to Isis royalties on Annual worldwide Net Sales of Products sold by AstraZeneca, its Affiliates or Sublicensees, on a country-by-country and Product-by-Product basis, in each case in the amounts as follows in Table 2 below (the “AstraZeneca Full Royalty”): Table 2 Royalty Tier Annual Worldwide Net Sales of Products from a Licensed Program Royalty Rate 1 For the portion of Annual Worldwide Net Sales < $[***] [***]%
Sample 1Sample 2
AutoNDA by SimpleDocs
AstraZeneca Full Royalty. As partial consideration for the rights granted to AstraZeneca hereunder, subject to the provisions of this Section 8.8.1 and Section 8.8.2, AstraZeneca will pay to Isis royalties on Annual worldwide Net Sales of Products sold by AstraZeneca, its Affiliates or Sublicensees, on a country-by-country and Product-by-Product basis, in each case in the amounts as follows in TABLE 4 below (the “AstraZeneca Full Royalty”): TABLE 4 Royalty Tier Annual Worldwide Net Sales of STAT3 Products High Response Outcome Royalty Rate Medium Response Outcome/Low Response Outcome Royalty Rate 1 For the portion of Annual Worldwide Net Sales < $[***] [***] % [***] % 2 For the portion of Annual Worldwide Net Sales > $[***] but < $[***] [***] % [***] % 3 For the portion of Annual Worldwide Net Sales > $[***] but < $[***] [***] % [***] % 4 For the portion of Annual Worldwide Net Sales > $[***] [***] % [***] % Royalty Tier Annual Worldwide Net Sales of [***] Products Royalty Rate 1 For the portion of Annual Worldwide Net Sales < $[***] [***] % 2 For the portion of Annual Worldwide Net Sales > $[***] but < $[***] [***] % 3 For the portion of Annual Worldwide Net Sales > $[***] [***] % Royalty Tier Annual Worldwide Net Sales of Oncology Products Royalty Rate 1 For the portion of Annual Worldwide Net Sales < $[***] [***] % 2 For the portion of Annual Worldwide Net Sales > $[***] but < $[***] [***] % 3 For the portion of Annual Worldwide Net Sales > $[***] but < $[***] [***] % 4 For the portion of Annual Worldwide Net Sales > $[***] [***] % Annual worldwide Net Sales will be calculated by taking the aggregate sum of Net Sales of Products for all countries worldwide.
Sample 1

Related to AstraZeneca Full Royalty

  • Know-How Royalty Notwithstanding the provisions of Section 5.4.1(a), in countries where the sale of Product by Merck or its Related Parties would not infringe a Valid Patent Claim, Merck shall pay royalty rates that shall be set at [***] of the applicable royalty rate determined according to Section 5.4.1(a). Such royalties shall be calculated after first calculating royalties under Section 5.4.1(a).

  • Sublicensee The term “Sublicensee” shall mean any third party to whom Licensee grants a sublicense or similar rights with respect to the rights conferred upon Licensee under this Agreement, as contemplated by Section 2.3. In addition, “Sublicensee” shall include any and all further third party Sublicensees that may be permitted under Section 2.3.

  • Licensee Licensee represents and warrants that:

  • Sublicense Fees Licensee will pay Sublicense Fees indicated in Section 3.1(e) of the Patent & Technology License Agreement on or before the Quarterly Payment Deadline for the Contract Quarter.

  • Royalty 8.1 In consideration of the rights granted under clause 2, the Licensee shall pay to the Licensor royalties, on each twelve month time period, first calculated from the date of execution of this Agreement, and calculated on a scale as follows:

  • Earned Royalty In addition, Alnylam will pay Stanford earned royalties on Net Sales as follows:

  • Sublicensees Licensee shall have the full right (but not the obligation) to sublicense those rights granted to it under Section 2.1 to a Third Party (a “Sublicensee”); provided, however, that, prior to the payment of the first milestone pursuant to Section 7.2, Licensee may not grant any such sublicense to any contract research organization conducting Clinical Trials of Products or any Third Parties conducting contract Manufacturing activities without Licensee’s prior written notice (at least twenty (20) Business Days in advance) to Lilly, which shall include a description of the rights to be granted and the purpose therefor, the identity of the Third Party and the countries involved, and Lilly’s prior written consent, but such consent shall only be required (i) until such time as Licensee is the holder of record for the Regulatory Materials related to Taladegib and (ii) to the extent such organization is not performing services for Licensee as of the Effective Date; and provided further, that Licensee shall remain responsible for the performance by any of its Sublicensees. With respect to any Sublicensee granted a sublicense to any Commercialization rights hereunder, Licensee shall ensure that each of its Sublicensees accepts in writing all applicable terms and conditions of this Agreement, including the non-compete, reporting, audit, inspection and confidentiality provisions hereunder. Each Sublicensee shall also be prohibited from further sublicensing. For the avoidance of doubt, (a) Licensee will remain directly responsible for all amounts owed to Lilly under this Agreement, and (b) each Sublicensee is subject to the negative and restrictive covenants set forth in Sections 2.3.1 and 2.5, respectively. Licensee hereby expressly waives any requirement that Lilly exhaust any right, power or remedy, or proceed against a subcontractor, for any obligation or performance hereunder prior to proceeding directly against Licensee.

  • Third Party Royalties Each party shall be responsible for all of its own costs of commercializing Products or licensing Intellectual Property Rights, including any payments to Third Parties for work done by such Third Parties or for licenses necessary for the manufacture, sale, or use of Products by a party or its Affiliates or sublicensees.

  • Royalties 8.1 In consideration of the license herein granted, LICENSEE shall pay royalties to LICENSOR as follows:

  • Royalty Payment In partial consideration of the grant of rights to Schering by ICN under this Agreement, Schering shall pay ICN a royalty in the following amount:

Time is Money Join Law Insider Premium to draft better contracts faster.